S. 832 119th Congress
EPIC Act of 2025
Latest action, Mar 4, 2025: Read twice and referred to the Committee on Finance.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
7 cosponsors
Sponsored by Thom Tillis (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
0 D · 7 R
- Democrat
- Republican
- Independent
Referred to: Senate: Finance Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
BOEHRINGER INGELHEIM USA CORPORATION
BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
7 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
DLA PIPER LLP (US)
7 reports
PHRMA
WILLIAMS AND JENSEN, PLLC
7 reports
7 reports
6 reports
6 reports
All 25 of 47 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| BAYER CORPORATION (CONSOLIDATED REPORT) | 7 | $14.8M | Q1 2025 | Q3 2026 | yes | |
| BOEHRINGER INGELHEIM USA CORPORATION | BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | 7 | $6.6M | Q1 2025 | Q3 2026 | yes |
| EMD SERONO INC | 7 | $5.4M | Q1 2025 | Q3 2026 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.9M | Q1 2025 | Q3 2026 | yes | |
| HEALTHCARE INSTITUTE OF NEW JERSEY | 7 | $333K | Q1 2025 | Q3 2026 | yes | |
| JOHNSON & JOHNSON SERVICES INC | 7 | $15.5M | Q1 2025 | Q3 2026 | yes | |
| LUNDBECK LLC | 7 | $1.1M | Q1 2025 | Q3 2026 | yes | |
| NEUROCRINE BIOSCIENCES, INC | 7 | $6.4M | Q1 2025 | Q3 2026 | yes | |
| NOVARTIS | 7 | $14.0M | Q1 2025 | Q3 2026 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | DLA PIPER LLP (US) | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $64.5M | Q1 2025 | Q3 2026 | yes | |
| PHRMA | WILLIAMS AND JENSEN, PLLC | 7 | $350K | Q1 2025 | Q3 2026 | yes |
| TAKEDA PHARMACEUTICALS AMERICA INC | 7 | $7.5M | Q1 2025 | Q3 2026 | yes | |
| ACADIA PHARMACEUTICALS | 6 | $3.6M | Q4 2025 | Q3 2026 | yes | |
| BIOGEN | 6 | $6.6M | Q1 2025 | Q3 2026 | yes | |
| HARMONY BIOSCIENCES | 6 | $1.1M | Q4 2025 | Q3 2026 | yes | |
| JOB CREATORS NETWORK | HARNED STRATEGIES LLC | 6 | $37K | Q1 2025 | Q2 2026 | yes |
| NOVARTIS | DLA PIPER LLP (US) | 6 | $0 | Q4 2025 | Q3 2026 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | LMH STRATEGIC SOLUTIONS | 6 | $0 | Q4 2025 | Q3 2026 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | CROSSROADS STRATEGIES, LLC | 6 | $0 | Q4 2025 | Q3 2026 | yes |
| PUBLIC CITIZEN | 6 | $548K | Q1 2025 | Q2 2026 | yes | |
| CONSERVATIVES FOR PROPERTY RIGHTS | ELITE STRATEGIC SERVICES | 5 | $188K | Q1 2025 | Q1 2026 | yes |
| NOVARTIS, INC. | FORBES-TATE | 5 | $0 | Q4 2025 | Q3 2026 | yes |
| NOVARTIS, INC. | TODD STRATEGY GROUP | 5 | $0 | Q4 2025 | Q2 2026 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | ADVANCED POLICY CONSULTING, LLC | 5 | $200K | Q4 2025 | Q3 2026 | yes |